Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENRICH phase 2 study of BRII-179 + BRII-835 + peginterferon alfa-2b in chronic hepatitis B
CTR20242310Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Aug 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BRII-179, elebsiran, peginterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by Brii Biosciences. Started Aug 2024; status: completed.
02
Drugs
BRII-179elebsiranpeginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20242310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242310.